Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Keverprazan Dual Therapy vs Quadruple Therapy for H. pylori Eradication
NCT07750938Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2026
- Primary completion
- Jul 2028
01
Overview
Phase 4, randomised, open-label trial of keverprazan in Helicobacter pylori infection (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Helicobacter pylori Eradication Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07750938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750938.